Shalini Sharp

2017 - Ultragenyx Pharmaceutical

In 2017, Shalini Sharp earned a total compensation of $2.6M as Chief Financial Officer and Executive Vice President at Ultragenyx Pharmaceutical, a 34% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$188,315
Option Awards$1,541,879
Salary$455,785
Stock Awards$424,043
Other$32,697
Total$2,642,719

Sharp received $1.5M in option awards, accounting for 58% of the total pay in 2017.

Sharp also received $188.3K in non-equity incentive plan, $455.8K in salary, $424K in stock awards and $32.7K in other compensation.

Rankings

In 2017, Shalini Sharp's compensation ranked 4,207th out of 14,666 executives tracked by ExecPay. In other words, Sharp earned more than 71.3% of executives.

ClassificationRankingPercentile
All
4,207
out of 14,666
71st
Division
Manufacturing
1,472
out of 5,768
75th
Major group
Chemicals And Allied Products
421
out of 2,074
80th
Industry group
Drugs
322
out of 1,730
81st
Industry
Pharmaceutical Preparations
256
out of 1,329
81st
Source: SEC filing on April 27, 2018.

Sharp's colleagues

We found five more compensation records of executives who worked with Shalini Sharp at Ultragenyx Pharmaceutical in 2017.

2017

Emil Kakkis

Ultragenyx Pharmaceutical

Chief Executive Officer

2017

Jayson Dallas

Ultragenyx Pharmaceutical

Chief Commercial Officer and Executive Vice President

2017

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officers and Executive Vice President

2017

John Pinion

Ultragenyx Pharmaceutical

Chief Quality Officer and Executive Vice President of Translational Sciences

2017

Karah Parschauer

Ultragenyx Pharmaceutical

General Counsel

News

In-depth

You may also like